Efficiently enhancing ferroptosis-mediated immunosensitization in lung cancer by an inhalable immune activation nanoplatform.

ABSTRACT: Immune checkpoint blockade therapy holds promise for inducing lung cancer regression, but its effectiveness is often limited due to the immunosuppressive tumor microenvironment (ITME). Ferroptosis can remodel the ITME and enhance immunotherapy, but traditional inducers exhibit weak immune modulation due to off-target toxicity and low drug concentrations at the tumor site, resulting in poor efficacy. To address these challenges, we explore an inhalable immune activation nanoplatform, named LMS, designed to enhance ferroptosis-mediated immunosensitization in lung cancer. LMS owns high ferroptosis inducer loading and multienzyme catalytic activity. By nebulization delivery, we demonstrate that LMS can fast and efficiently delivery Statins to lung cancer with minimal systemic toxicity. LMS eff

SUBMITTER: Chen Z 

PROVIDER: S-EPMC12681739 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature